Exome sequencing: value is in the eye of the beholder
- 14 October 2019
- journal article
- editorial
- Published by Elsevier BV in Genetics in Medicine
- Vol. 22 (2), 280-282
- https://doi.org/10.1038/s41436-019-0674-z
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disordersGenetics in Medicine, 2019
- Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS)Genetics in Medicine, 2019
- Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testingJournal of Genetic Counseling, 2019
- Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence citedGenetics in Medicine, 2019
- Genome-wide sequencing in acutely ill infants: genomic medicine’s critical application?Genetics in Medicine, 2018
- Genetic Test Availability And Spending: Where Are We Now? Where Are We Going?Health Affairs, 2018
- Early-Life Epilepsies and the Emerging Role of Genetic TestingJAMA Pediatrics, 2017
- Payer coverage policies for multigene testsNature Biotechnology, 2017
- Payer view of personalized medicineAmerican Journal of Health-System Pharmacy, 2016
- What is the clinical utility of genetic testing?Genetics in Medicine, 2006